1. Bennett Ch, Evens AM, Andritsos LA, et al. Haematological malignancies developing in previously healthy individuals who received haematopoietic growth factors: report from the Research on Adverse Drug Events and Reports (RADAR). Br J Haematol 2006; 135: 642–650.
2. Hershman D, Neugut AI, Jacobson JS, et al. Acute Myeloid leukemia or Myelodysplastic Syndrome Following Use of Granulocyte Colony-Stimulating Factors during Brest Cancer Adjuvant Chemotherapy. J Natl Cancer Inst 2007; 99: 196–205.
3. Cavallaro AM, Lilleby K, Majolino I, et al. Three to six year follow-up of normal donors who received recombinant human granulocyte colony-stimulating factor. Bone Marrow Transplant 2000; 25: 85–89.
4. Tassi C, Tazzari PL, Bonifazi F, et al. Short- and long-term haematological surveillance of healthy donors of allogeneic peripheral haematopoietic progenitors mobilized with G-CSF: a single institution prospective study. Bone Marrow Transplant 2005; 736: 289–294.
5. LeBlanc R, Roy J, Demers C, et al. A prospective study of G-CSF effects on hemostasis in allogeneic blood stem cell donors. Bone Marrow Transplant 1999; 23: 991–996.
6. Nuamah NM, Goker H, Kilic YA, et al. Spontaneous splenic rupture in a healthy allogeneic donor of peripheral-blood stem cell following the administration of granulocyte colony-stimulating factor (g-csf). A case report and review of the literature. Haematologica 2006; 91: 9–11.
7. Anderlini P, Chan FA, Champlin RE, et al. Long-term follow-up of normal peripheral blood progenitor cell donors treated with filgrastim: no evidence of increased risk of leukemia development. Bone Marrow Transplant 2002; 30: 661-663.
8. Makita K, Ohta K, Mugitani A, et al. Acute myelogenous leukemia in a donor after granulocyte colony-stimulating factor-primed peripheral blood stem cell harvest. Bone Marrow Transplant 2004; 33: 661–665.
9. Rauscher GH, Sandler DP, Poole C, et al. Family History of Cancer and Incidence of Acute Leukemia in Adults. Am J Epid 2002; 156: 517–526.
10. Segel GB, Lichtman MA. Familial (inherited) leukemia, lymphoma, and myeloma: an overview. Blood Cells, Molecules, and Diseases 2004; 32: 246–261.
11. Confer D, Miller JP. Long-term safety of filgrastim (rhG-CSF) administration. Br J Haematol 2006; 137: 77–78.
12. Tigue CC, Trifilio SM, Tallman MS, et al. Long-term safety of filgrastim (rhG-CSF) administration: response to Confer & Miller and Bache & Zander. Br J Haematol 2006; 137: 79–80.
13. Grupp SA, Frangoul H, Wall D, et al. Use of G-CSF in matched sibling donor pediatric allogeneic transplantation: a consensus statement from the Children’s Oncology Group (COG) transplant discipline committee and Pediatric Blood and Marrow transplant Consortium (PBMTC) executive committee. Pediatr Blood Cancer 2006; 46:414–421.
14. Hasenclever D, Sextro M. Safety of AlloPBPCT donors: biometrical considerations on monitoring long term risks. Bone Marrow Transplant 1996; 17: S28–S30.
15. Rosenberg PS, Alter BP, Bolyard AA, et al. The incidence of leukemia and mortality from sepsis in patients with severe congenital neutropenia receiving long-term G-CSF therapy. Blood 2006; 107: 4628–4635.
16. Pulsipher MA, Nagler A, Iannone R, Nelson RM. Weighing the risk of G-CSF administration, leukapheresis, and standard marrow harvest: ethical and safety considerations for normal pediatric hematopoietic cell donors. Pediatr Blood Cancer 2006; 46: 422–433.
17. Heil G, Hoelzer D, Sanz MA, et al. A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for Adults with de novo acute myeloid leukemia. Blood 1997; 90: 4710–4718.
18. Casadevall N, Durieux P, Dubois S, et al. Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial. Blood 2004; 104: 321–327.
19. Greenberg P, Taylor K, Larson R, et al. Phase III randomized multicenter trial of G-CSF vs. observation for myelodysplastic syndromes (MDS). Blood 1993; suppl 1, 82: 196a.
20. Usuki K, Urabe A, Masaoka T, et al. Efficacy of granulocyte colony-stimulating factor in the treatment of acute myelogenous leukaemia: a multicentre randomized study. Br J Haematol 2002; 116: 103–112.
21. Nagler A, Korenstein-Ilan A, Amiel A, et al. Granulocyte colony-stimulating factor generates epigenetic and genetic alterations on lymphocytes of normal volunteer donors of stem cells. Experimental Hematology 2004; 32: 122–130.
22. Shapira MY, Kaspler P, Samuel S, et al. Granulocyte Colony Stimulating Factor Does Not Induce Long-Term DNA Instability in Healthy Peripheral Blood Stem Cell Donors. Am J Hematol 2003; 73: 33–36.
23. Kaplinsky C, Trakhtenbrot L, Hardan I, et al. Tetraploid myeloid cells in donors of peripheral blood stem cells treated with rhG-CSF. Bone Marrow Transplant 2003; 32: 31–34.
24. Weaver CH, Birch R, Greco FA, et al. Mobilization and harvesting of peripheral stem cells: randomized evaluations of different doses of filgrastim. Br J Haematol 1998; 100: 338–347.
25. Engelhardt M, Bertz H, Afting M, et al. High- versus standard-dose filgrastim (rhG-CSF) for mobilization of peripheral-blood progenitor cells from allogeneic donors and CD34+ immunoselection. J Clin Oncol 1999; 17: 2160–2172.
26. Kröger N, Renges H, Sonnenberg S, et al. Stem ell mobilization with 16 μg/kg vs. 10 μg/kg of G-CSF for allogeneic transplantation in healthy donors. Bone Marrow Transplant 2002; 29: 727–730.
27. Russell N, Gratwohl A, Schmitz N. The place of blood stem cells in allogeneic transplantation. Br J Haematol 1996; 93: 747–753.
28. Stroncek DF, Clay ME, Petzoldt ML, et al. Treatment of normal individuals with granulocyte-colony-stimulating factor: donor experiences and the effects on peripheral blood CD34+ cell counts and on the collection of peripheral blood stem cells. Transfusion 1996; 36: 601–610.
29. Martínez C, Urbano-Ispizua A, Marín P, et al. Efficacy and toxicity of a high dose G-CSF schedule for peripheral blood progenitor cell mobilization in healthy donors. Bone Marrow Transplant 1999; 24: 1273–1278.
30. Haas M, Kerst JM, Schoot E, et al. Granulocyte colony-stimulating factor administration to healthy volunteers: analysis of the immediate activating effects on circulating neutrophils. Blood 1994; 84: 3885–3894.
31. Stute N, Santana VM, Rodman JH, et al. Pharmacokinetics of subcutaneous recombinant human granulocyte colony– stimulating factor in children. Blood 1992; 79: 2849–2854.
32. Watts MJ, Addison I, Ings SJ et, al. Optimal timing for collection of PBSC after glycosylated G-CSF administration. Bone Marrow Transplant 1998; 21: 365–368.
33. Faulkner LB, Tucci F, Tamburini A, et al. G-CSF serum pharmacokinetics during peripheral blood progenitor cell mobilization: neutrophil count-adjusted dosage might potentially improve mobilization and be more cost-effective. Bone Marrow Transplant 1998; 21: 1091–1095.
34. Kröger N, Renges H, Krüger W, et al. A randomized comparison of once versus twice daily recombinant human granulocyte colony-stimulating factor (filgrastim) for stem cell mobilization in healthy donors for allogeneic transplantation. Br J Haematol 2000; 111: 761–765.
35. Arbona C, Prosper F, Benet I, et al. Comparison between once a day vs. twice a day G-CSF for mobilization of peripheral blood progenitor cells in normal donors for allogeneic PBSC transplantation. Bone Marrow Transplant 1998; 22: 39–45.